{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:15:42Z","timestamp":1738818942712,"version":"3.37.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,12,13]],"date-time":"2008-12-13T00:00:00Z","timestamp":1229126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00228-008-0597-0","type":"journal-article","created":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T17:08:09Z","timestamp":1229101689000},"page":"411-417","source":"Crossref","is-referenced-by-count":10,"title":["Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?"],"prefix":"10.1007","volume":"65","author":[{"given":"Alexander","family":"Jetter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rodamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Tomalik-Scharte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"S\u00f6rgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,13]]},"reference":[{"key":"597_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.tpj.6500053","volume":"2","author":"NJ Butcher","year":"2002","unstructured":"Butcher NJ, Boukouvala S, Sim E et al (2002) Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2:30\u201342","journal-title":"Pharmacogenomics J"},{"key":"597_CR2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87\u2013114","journal-title":"Pharmacol Rev"},{"key":"597_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-2797(00)00203-9","volume":"129","author":"CA Pritsos","year":"2000","unstructured":"Pritsos CA (2000) Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact 129:195\u2013208","journal-title":"Chem Biol Interact"},{"key":"597_CR4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.21.83","volume":"21","author":"S Kitamura","year":"2006","unstructured":"Kitamura S, Sugihara K, Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83\u201398","journal-title":"Drug Metab Pharmacokinet"},{"key":"597_CR5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/FPC.0b013e3282f55e2e","volume":"18","author":"M Kudo","year":"2008","unstructured":"Kudo M, Moteki T, Sasaki T et al (2008) Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics 18:243\u2013251","journal-title":"Pharmacogenet Genomics"},{"key":"597_CR6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00228-003-0653-8","volume":"59","author":"E Aklillu","year":"2003","unstructured":"Aklillu E, Carrillo JA, Makonnen E et al (2003) Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol 59:533\u2013536","journal-title":"Eur J Clin Pharmacol"},{"key":"597_CR7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/clpt.1983.45","volume":"33","author":"DM Grant","year":"1983","unstructured":"Grant DM, Tang BK, Kalow W (1983) Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 33:355\u2013359","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/clpt.1988.130","volume":"44","author":"BG Hardy","year":"1988","unstructured":"Hardy BG, Lemieux C, Walker SE et al (1988) Interindividual and intraindividual variability in acetylation: characterization with caffeine. Clin Pharmacol Ther 44:152\u2013157","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/clpt.1983.80","volume":"33","author":"DM Grant","year":"1983","unstructured":"Grant DM, Tang BK, Kalow W (1983) Variability in caffeine metabolism. Clin Pharmacol Ther 33:591\u2013602","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00228-003-0718-8","volume":"60","author":"A Jetter","year":"2004","unstructured":"Jetter A, Kinzig-Schippers M, Illauer M et al (2004) Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur J Clin Pharmacol 60:17\u201321","journal-title":"Eur J Clin Pharmacol"},{"key":"597_CR11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1124\/dmd.105.005272","volume":"33","author":"D Tomalik-Scharte","year":"2005","unstructured":"Tomalik-Scharte D, Jetter A, Kinzig-Schippers M et al (2005) Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33:1859\u20131866","journal-title":"Drug Metab Dispos"},{"key":"597_CR12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/clpt.1991.82","volume":"49","author":"BK Tang","year":"1991","unstructured":"Tang BK, Kadar D, Qian L et al (1991) Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 49:648\u2013657","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.1991.8","volume":"49","author":"W Kalow","year":"1991","unstructured":"Kalow W, Tang BK (1991) Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44\u201348","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR14","first-page":"1","volume":"29","author":"E Diletti","year":"1991","unstructured":"Diletti E, Hauschke D, Steinijans VW (1991) Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29:1\u20138","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"597_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-199604000-00001","volume":"6","author":"A Rostami-Hodjegan","year":"1996","unstructured":"Rostami-Hodjegan A, Nurminen S, Jackson PR et al (1996) Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 6:121\u2013149","journal-title":"Pharmacogenetics"},{"key":"597_CR16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1365-2125.2003.01730.x","volume":"55","author":"A Ny\u00e9ki","year":"2003","unstructured":"Ny\u00e9ki A, Buclin T, Biollaz J et al (2003) NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. Br J Clin Pharmacol 55:62\u201367","journal-title":"Br J Clin Pharmacol"},{"key":"597_CR17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1365-2125.1986.tb05222.x","volume":"21","author":"DM Grant","year":"1986","unstructured":"Grant DM, Tang BK, Campbell ME et al (1986) Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 21:454\u2013458","journal-title":"Br J Clin Pharmacol"},{"key":"597_CR18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/clpt.1991.176","volume":"50","author":"W Kalow","year":"1991","unstructured":"Kalow W, Tang BK (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508\u2013519","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/clpt.1993.63","volume":"53","author":"W Kalow","year":"1993","unstructured":"Kalow W, Tang BK (1993) The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53:503\u2013514","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2125.1997.53711.x","volume":"43","author":"DJ Birkett","year":"1997","unstructured":"Birkett DJ, Miners JO, Valente L et al (1997) 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect. Br J Clin Pharmacol 43:197\u2013200","journal-title":"Br J Clin Pharmacol"},{"key":"597_CR21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s002280050569","volume":"54","author":"P Fuchs","year":"1999","unstructured":"Fuchs P, Haefeli WE, Ledermann HR et al (1999) Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol 54:869\u2013876","journal-title":"Eur J Clin Pharmacol"},{"key":"597_CR22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1067\/mcp.2000.109519","volume":"68","author":"DS Streetman","year":"2000","unstructured":"Streetman DS, Bleakley JF, Kim JS et al (2000) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the \"Cooperstown cocktail\". Clin Pharmacol Ther 68:375\u2013383","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0009-9236(03)00229-7","volume":"74","author":"S Chainuvati","year":"2003","unstructured":"Chainuvati S, Nafziger AN, Leeder JS et al (2003) Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the \"Cooperstown 5+1 cocktail\". Clin Pharmacol Ther 74:437\u2013447","journal-title":"Clin Pharmacol Ther"},{"key":"597_CR24","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1128\/AAC.50.4.1130-1135.2006","volume":"50","author":"JD Ma","year":"2006","unstructured":"Ma JD, Nafziger AN, Villano SA et al (2006) Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 50:1130\u20131135","journal-title":"Antimicrob Agents Chemother"},{"key":"597_CR25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2125.2003.01725.x","volume":"55","author":"F Vrtic","year":"2003","unstructured":"Vrtic F, Haefeli WE, Drewe J et al (2003) Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. Br J Clin Pharmacol 55:191\u2013198","journal-title":"Br J Clin Pharmacol"},{"key":"597_CR26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5414\/CPP45431","volume":"45","author":"J Rengelshausen","year":"2007","unstructured":"Rengelshausen J, G\u00f6ggelmann C, Burhenne J et al (2007) Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. Int J Clin Pharmacol Ther 45:431\u2013437","journal-title":"Int J Clin Pharmacol Ther"},{"key":"597_CR27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.1987.189","volume":"42","author":"BK Tang","year":"1987","unstructured":"Tang BK, Kadar D, Kalow W (1987) An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 42:509\u2013513","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0597-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-008-0597-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0597-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T04:55:51Z","timestamp":1738817751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-008-0597-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,13]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1007\/s00228-008-0597-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2008,12,13]]}}}